RecallHawk

ASTAGRAF XL (TACROLIMUS EXTENDED-RELEASE CAPSULES)

ASTELLAS

Summary

FDA approved ASTAGRAF XL (TACROLIMUS EXTENDED-RELEASE CAPSULES) by ASTELLAS. NDA (New Drug) approval (Labeling) on 2023-09-14. CAPSULE, EXTENDED RELEASE, ORAL.

Details

Source

Drug Approval

External ID

NDA204096-11

Action Date

2023-09-14

Status

Approved

Category

drug

Product Code

NDA (New Drug)

Product Description

ASTAGRAF XL (generic: TACROLIMUS EXTENDED-RELEASE CAPSULES), CAPSULE, EXTENDED RELEASE, ORAL. Application: NDA204096

Company

Context & Analysis

ASTELLAS has 6 FDA actions in our database.

Frequently Asked Questions

How often does ASTELLAS have FDA actions?

ASTELLAS has 6 FDA actions in our database, including 0 recalls and 0 device clearances.

Where can I find the official FDA record?

The official record is available on FDA.gov. Search for "NDA204096-11" on FDA.gov for the full record. You can also use the openFDA API to query this record programmatically.

Want to know the moment something like this happens?

Get alerts for drug

Related Actions